Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / A Methylation Panel for Bladder Cancer

A Methylation Panel for Bladder Cancer

258
Gazdar, AdiUT Southwestern Medical Center

No involved investigator sites defined.

Proteomics
Prostate and Urologic Cancers Research Group

Participate in a prevalidation study for methylation based detection of bladder cancer. In addition, a panel of three markers identified will be evaluated for their ability to a) identify bladder cancer patients from those with benign urologic disease; b) identify patients with superficial (papillary) cancers from those with high grade invasive cancers

1) Participate in a prevalidation study for methylation based detection of bladder cancer. 2) Collect voided urine specimens from patients with a) invasive carcinomas, b) non-invasive carcinomas, and c) patients with urologic diseases who are free of cancer, including patients with hematuria 3) Test the panel of three methylation markers described in the Preliminary DAta for their ability to identify individuals with bladder cancer and to differentiate between invasive and non-invasive cancers

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.

Announcement 01/30/2017

Please visit http://www.compass. fhcrc.org/meeting/reg_edrn/edrnsc.aspx for information and to register for the 31st EDRN Steering Committee Meeting in Tempe, AZ, from March 6-9, 2017.

Announcement